{"id":78541,"date":"2022-03-10T12:16:33","date_gmt":"2022-03-10T18:16:33","guid":{"rendered":"https:\/\/milesfortis.com\/?p=78541"},"modified":"2022-03-10T12:16:33","modified_gmt":"2022-03-10T18:16:33","slug":"78541","status":"publish","type":"post","link":"https:\/\/milesfortis.com\/?p=78541","title":{"rendered":""},"content":{"rendered":"

Oh to those people pushing the vaxx because it ‘safe’ or something? This is from The Lancet<\/em>, which\u00a0is a weekly peer-reviewed<\/strong> general medical journal.<\/p>\n

\n

Comment O’ The Day (from a GP MD)<\/p>\n

1% of those who had a reaction to the vaccine are dead.
\nSorry if that was not made clear. But remember the cut off at the CDC for pulling a vaccine or medicine from the market is 50 deaths. Hit that magic number and it is off the market.<\/p>\n

The jabs in all their glory are far above that. And this is all being done under a EUA for a disease that is not that lethal. So you get a reaction to the jab, depending on the type of one given, you stand a 1% chance of dying.<\/strong> Remember, the VAERS data is skewed to make those numbers lower.\u00a0The vaccine is not safe given the usual definition per the CDC.<\/p>\n

My biggest problem is they had this data and it was not disclosed to people in terms of informed consent. How many people would have taken the jab if they were told: \u201cThe vaccine is considered safe, but 1% of those who get a reaction are dead.\u201d<\/em><\/p>\n

Mind you, the vaccine failed to contain the disease and was considered not effective in preventing morbidity after 6 months. Why was this data not discussed earlier?\u00a0Well that is pretty clear in that when it came to consent time, most would have said \u201cI\u2019ll just take my chances.\u201d<\/em><\/span><\/p>\n

\n

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe<\/a><\/p>\n

\n

PDF download<\/a><\/p>\n

Table 1 <\/span>Characteristics of reports received and processed by VAERS for mRNA COVID-19 vaccines<\/span><\/div>\n
\n\n\n\n\n\n\n\n\n\n
<\/th>\n<\/th>\nBoth mRNA vaccines (n=340\u2008522)<\/strong><\/p>\n
*<\/a><\/div>\n<\/th>\n
BNT162b2 vaccine (n=164\u2008669)<\/strong><\/th>\nmRNA-1273 vaccine (n=175\u2008816)<\/strong><\/th>\n<\/tr>\n<\/thead>\n
Category<\/strong><\/td>\n<\/tr>\n
Non-serious<\/td>\n313\u2008499 (92\u00b71%)<\/td>\n150\u2008486 (91\u00b74%)<\/td>\n162\u2008977 (92\u00b77%)<\/td>\n<\/tr>\n
Serious, including death<\/td>\n27\u2008023 (7\u00b79%)<\/td>\n14\u2008183 (8\u00b76%)<\/td>\n12\u2008839 (7\u00b73%)<\/td>\n<\/tr>\n
Serious, excluding death<\/td>\n22\u2008527 (6\u00b76%)<\/td>\n12\u2008078 (7\u00b73%)<\/td>\n10\u2008448 (5\u00b79%)<\/td>\n<\/tr>\n
Death<\/strong><\/td>\n4496 (1\u00b73%)<\/strong><\/td>\n2105 (1\u00b73%)<\/strong><\/td>\n2391 (1\u00b74%)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Summary<\/span><\/h2>\n
\n

Background<\/h3>\n
In December, 2020, two mRNA-based COVID-19 vaccines were authorised for use in the USA.
\nWe aimed to describe US surveillance data collected through the Vaccine Adverse Event Reporting System (VAERS), a passive system, and v-safe, a new active system, during the first 6 months of the US COVID-19 vaccination programme.<\/div>\n<\/div>\n<\/section>\n
<\/div>\n

<\/p>\n

Methods<\/span><\/div>\n
\n
\n
In this observational study, we analysed data reported to VAERS and v-safe during Dec 14, 2020, to June 14, 2021. VAERS reports were categorised as non-serious, serious, or death. Reporting rates were calculated using numbers of COVID-19 doses administered as the denominator. We analysed v-safe survey reports from days 0\u20137 after vaccination for reactogenicity, severity (mild, moderate, or severe), and health impacts (ie, unable to perform normal daily activities, unable to work, or received care from a medical professional).<\/div>\n

Findings<\/h3>\n
During the study period, 298\u2009792\u2009852 doses of mRNA vaccines were administered in the USA. VAERS processed 340\u2009522 reports: 313\u2009499 (92\u00b71%) were non-serious, 22\u2009527 (6\u00b76%) were serious (non-death), and 4496 (1\u00b73%) were deaths. Over half of 7\u2009914\u2009583 v-safe participants self-reported local and systemic reactogenicity, more frequently after dose two (4\u2009068\u2009447 [71\u00b77%] of 5\u2009674\u2009420 participants for local reactogenicity and 4\u2009018\u2009920 [70\u00b78%] for systemic) than after dose one (4\u2009644\u2009989 [68\u00b76%] of 6\u2009775\u2009515 participants for local reactogenicity and 3\u2009573\u2009429 [52\u00b77%] for systemic). Injection-site pain (4\u2009488\u2009402 [66\u00b72%] of 6\u2009775\u2009515 participants after dose one and 3\u2009890\u2009848 [68\u00b76%] of 5\u2009674\u2009420 participants after dose two), fatigue (2\u2009295\u2009205 [33\u00b79%] participants after dose one and 3\u2009158\u2009299 participants [55\u00b77%] after dose two), and headache (1\u2009831\u2009471 [27\u00b70%] participants after dose one and 2\u2009623\u2009721 [46\u00b72%] participants after dose two) were commonly reported during days 0\u20137 following vaccination. Reactogenicity was reported most frequently the day after vaccination; most reactions were mild. More reports of being unable to work, do normal activities, or of seeking medical care occurred after dose two (1\u2009821\u2009421 [32\u00b71%]) than after dose one (808\u2009963 [11\u00b79%]); less than 1% of participants reported seeking medical care after vaccination (56\u2009647 [0\u00b78%] after dose one and 53\u2009077 [0\u00b79%] after dose two).<\/div>\n

Interpretation<\/h3>\n
Safety data from more than 298 million doses of mRNA COVID-19 vaccine administered in the first 6 months of the US vaccination programme show that most reported adverse events were mild and short in duration.<\/div>\n

Funding<\/h3>\n
US Centers for Disease Control and Prevention.<\/div>\n<\/div>\n<\/section>\n
\n
\n